ION717
Asset
Intrathecal antisense oligonucleotide reducing expression of PRNP messenger RNA to prevent prion pathology.
- Stage
- Phase 1
- Modality
- Oligonucleotide
- Target
- PRNP
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Prion disease
Phase 1, Active not recruiting, NCT06153966, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Trials1
- Evidence for its targets2
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.
Updated 7 Oct 2026, 2 sources